Rallybio Corporation (RLYB)
|Net Income (ttm)||-35.84M|
|Day's Range||10.05 - 11.53|
|52-Week Range||10.05 - 25.78|
|Price Target||30.00 (+172.7%)|
|Est. Earnings Date||Nov 15, 2021|
Rallybio is a clinical-stage biotechnology company built around a team of seasoned industry experts with a shared purpose and a track record of success in discovering, developing, manufacturing and delivering therapies that meaningfully improve the lives of patients suffering from severe and rare diseases. Since our launch in January 2018, we have acquired a portfolio of promising product candidates that consists of five programs, and we are focused on further expanding our portfolio with the goal of making a profound impact on the lives of eve... [Read more...]
Financial PerformanceFinancial Statements
According to 3 analysts, the average rating for Rallybio stock is "Strong Buy." The 12-month stock price forecast is 30.00, which is an increase of 172.73% from the latest price.
NEW HAVEN, Conn.--(BUSINESS WIRE)---- $RLYB #FNAIT--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transfor...
With the trading day more than halfway over, the broad markets had a roaring start to the week with the S&P 500 and Nasdaq hitting record intraday highs.
Viking Global leader Andreas Halvorsen (Trades, Portfolio) disclosed a stake in Rallybio Corp. ( RLYB , Financial) earlier this week, seeing a value opportunity in a newly public company.
Rallybio Corporation Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Pu...
NEW HAVEN, Conn.--(BUSINESS WIRE)-- #Rallybio--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming ...
Rallybio Corporation (Rallybio), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disease...
Rallybio Corporation has filed to go public with an IPO on the NASDAQ.
Fierce15 winner Rallybio establishes proof-of-concept in phase 1/2 study for rare fetal bleeding disorder
2018 Fierce15 winner Rallybio has established proof-of-concept for an antibody treatment aiming to prevent a rare disease that causes a mother’s immune system to attack her fetus or newborn child’s plat...